{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:59:31Z","timestamp":1790189971323,"version":"4.1.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"abstract":"<jats:p>\n                    We conducted research on the causal relationships between human immune cells and common urinary system tumors. This study conducted 2-sample Mendelian randomization analyses to determine the causal relationships between immune cell traits and the risk of kidney, bladder, and prostate cancers (PCs). Sensitivity analyses were used to validate the robustness of the results, focusing on pleiotropy and heterogeneity. These findings may inform early diagnosis and personalized immunotherapy for urinary system tumors. Our study identified 12 immune cell phenotypes associated with kidney cancer, including CD127\u2212 CD8br absolute cell (AC; odds ratio [OR]\u2005=\u20051.205, 95% confidence interval [CI]: 1.099\u20131.320,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20056.73\u2005\u00d7\u200510\n                    <jats:sup>\u22125<\/jats:sup>\n                    ); CD25 on CD39+ activated regulatory T cell (OR\u2005=\u20051.136, 95% CI: 1.037\u20131.244,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006); CD4 on TD CD4+ (OR\u2005=\u20051.102, 95% CI: 1.027\u20131.182,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.007); immunoglobulin D (IgD)+ CD38\u2212% lymphocyte (OR\u2005=\u20051.101, 95% CI: 1.031\u20131.177,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004); CD20 on IgD\u2212 CD38br (OR\u2005=\u20051.067, 95% CI: 1.017\u20131.120,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008); CD25 on B cell (OR\u2005=\u20051.067, 95% CI: 1.022\u20131.114,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004); HLA DR on B cell (OR\u2005=\u20050.929, 95% CI: 0.882\u20130.979,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006); HLA DR on CD33dim HLA DR+ CD11b\u2212 (OR\u2005=\u20050.924, 95% CI: 0.874\u20130.977,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.005); HLA DR on CD14+ CD16+ monocyte (OR\u2005=\u20050.947, 95% CI: 0.916\u20130.980,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002); CD62L\u2212 plasmacytoid DC %DC (OR\u2005=\u20050.906, 95% CI: 0.850\u20130.965,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002); CD11c on myeloid DC (OR\u2005=\u20050.904, 95% CI: 0.853\u20130.959,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20057.38\u2005\u00d7\u200510\n                    <jats:sup>\u22124<\/jats:sup>\n                    ); CD11c on CD62L+ myeloid DC (OR\u2005=\u20050.930, 95% CI: 0.881\u20130.981,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.008). Four immune cell phenotypes were associated with bladder cancer, including CD38dim% lymphocyte (OR\u2005=\u20051.081, 95% CI: 1.020\u20131.145,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009); HLA DR+ CD8br AC (OR\u2005=\u20050.940, 95% CI: 0.897\u20130.985,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009); IgD on unsw mem (OR\u2005=\u20050.908, 95% CI: 0.856\u20130.963,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.001). In the conventional dendritic cell group, FSC-A on granulocyte (OR\u2005=\u20050.897, 95% CI: 0.836\u20130.963,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.003). Six immune cell phenotypes were associated with PC, including CD19 on IgD\u2212 CD38\u2212 (OR\u2005=\u20051.080, 95% CI: 1.033\u20131.129,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20056.21\u2005\u00d7\u200510\n                    <jats:sup>\u22124<\/jats:sup>\n                    ); CD27 on CD20\u2212 (OR\u2005=\u20051.040, 95% CI: 1.010\u20131.072,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009); CD86+ plasmacytoid DC %DC (OR\u2005=\u20051.053, 95% CI: 1.013\u20131.094,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009); CD25 on IgD+ CD38\u2212 (OR\u2005=\u20050.974, 95% CI: 0.960\u20130.988,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20052.59\u2005\u00d7\u200510\n                    <jats:sup>\u22124<\/jats:sup>\n                    ); CD25hi CD45RA+ CD4 not regulatory T cell AC (OR\u2005=\u20050.962, 95% CI: 0.937\u20130.989,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006); CD127 on CD28\u2212 CD8br (OR\u2005=\u20050.952, 95% CI: 0.920\u20130.984,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004). Our study, utilizing Mendelian randomization genetic methods, has demonstrated the causal associations between immune cell phenotypes and kidney cancer, bladder cancer, and PC, providing guidance for future clinical diagnosis and treatment of these 3 malignant tumors of the urinary system.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044297","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:02:10Z","timestamp":1757970130000},"page":"e44297","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Causal relationships between immune cells and common urinary system tumors: A bidirectional analysis of Mendelian randomization"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7640-5963","authenticated-orcid":false,"given":"Zhaohui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Inner Mongolia Forestry General Hospital, The Second Clinical Medical School of Inner Mongolia Minzu University, Yakeshi, Inner Mongolia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3387-1894","authenticated-orcid":false,"given":"Jingjing","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Inner Mongolia Forestry General Hospital, The Second Clinical Medical School of Inner Mongolia Minzu University, Yakeshi, Inner Mongolia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Inner Mongolia Forestry General Hospital, The Second Clinical Medical School of Inner Mongolia Minzu University, Yakeshi, Inner Mongolia, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0435-2695","authenticated-orcid":false,"given":"Lijun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Inner Mongolia Forestry General Hospital, The Second Clinical Medical School of Inner Mongolia Minzu University, Yakeshi, Inner Mongolia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260923","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260923","first-page":"17","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment.","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape.","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age.","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy.","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer.","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point.","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"R10-20260923","doi-asserted-by":"crossref","first-page":"101296","DOI":"10.1016\/j.isci.2020.101296","article-title":"Immune cell associations with cancer risk.","volume":"23","author":"Palomero","year":"2020","journal-title":"iScience"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"7946","DOI":"10.3390\/ijms24097946","article-title":"The tumor immune microenvironment in clear cell renal cell carcinoma.","volume":"24","author":"Monjaras-Avila","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.18632\/aging.202327","article-title":"Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.","volume":"13","author":"Yan","year":"2020","journal-title":"Aging (Milano)"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","article-title":"The tumor immune contexture of prostate cancer.","volume":"10","author":"Vitkin","year":"2019","journal-title":"Front Immunol"},{"key":"R14-20260923","first-page":"325","article-title":"Role of immunohistochemistry in subtyping renal cell carcinomas with overlapping morphological features.","volume":"30","author":"Tariq","year":"2018","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/PAS.0b013e31821e25cd","article-title":"Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study.","volume":"35","author":"Al-Ahmadie","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization.","volume":"318","author":"Emdin","year":"2017","journal-title":"JAMA"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jrsm.1346","article-title":"Meta\u2010analysis and Mendelian randomization: a review.","volume":"10","author":"Bowden","year":"2019","journal-title":"Res Synth Methods"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2009.812","article-title":"Mendelian randomization: nature\u2019s randomized trial in the post\u2013genome era.","volume":"301","author":"Thanassoulis","year":"2009","journal-title":"JAMA"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"e1009238","DOI":"10.1371\/journal.pcbi.1009238","article-title":"Ten simple rules for conducting a mendelian randomization study.","volume":"17","author":"Gagliano Taliun","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population.","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ng.3368","article-title":"Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers.","volume":"47","author":"Sidore","year":"2015","journal-title":"Nat Genet"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12888-023-05081-4","article-title":"Causal role of immune cells in schizophrenia: Mendelian randomization (MR) study.","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Psychiatry"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies.","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","article-title":"Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors.","volume":"30","author":"Burgess","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"R26-20260923","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data.","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"key":"R27-20260923","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"R28-20260923","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator.","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"R29-20260923","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption.","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int J Epidemiol"},{"key":"R30-20260923","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/sim.7221","article-title":"A framework for the investigation of pleiotropy in two\u2010sample summary data Mendelian randomization.","volume":"36","author":"Bowden","year":"2017","journal-title":"Stat Med"},{"key":"R31-20260923","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023.","volume":"4","author":"Burgess","year":"2023","journal-title":"Wellcome Open Res"},{"key":"R32-20260923","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method.","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"R33-20260923","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/EDE.0000000000000559","article-title":"Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants.","volume":"28","author":"Burgess","year":"2017","journal-title":"Epidemiology"},{"key":"R34-20260923","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1158\/0008-5472.CAN-05-3766","article-title":"Inhibitory effects of B cells on antitumor immunity.","volume":"66","author":"Inoue","year":"2006","journal-title":"Cancer Res"},{"key":"R35-20260923","doi-asserted-by":"crossref","first-page":"djw144","DOI":"10.1093\/jnci\/djw144","article-title":"Genomic analysis of immune cell infiltrates across 11 tumor types.","volume":"108","author":"Iglesia","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"R36-20260923","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 elicits IFN\u03b3-dependent tumor immune surveillance.","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"R37-20260923","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cellimm.2010.09.010","article-title":"Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70.","volume":"266","author":"Heckel","year":"2011","journal-title":"Cell Immunol"},{"key":"R38-20260923","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1007\/s13277-015-4687-1","article-title":"Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.","volume":"37","author":"Cai","year":"2016","journal-title":"Tumour Biol"},{"key":"R39-20260923","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ajt.14013","article-title":"Prospective analyses of circulating B cell subsets in ABO-compatible and ABO-incompatible kidney transplant recipients.","volume":"17","author":"Schl\u00f6\u00dfer","year":"2017","journal-title":"Am J Transplant"},{"key":"R40-20260923","doi-asserted-by":"crossref","first-page":"e20200851","DOI":"10.1084\/jem.20200851","article-title":"B cells and cancer: to B or not to B?","volume":"218","author":"Fridman","year":"2021","journal-title":"J Exp Med"},{"key":"R41-20260923","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00262-007-0318-z","article-title":"Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.","volume":"56","author":"Griffiths","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"R42-20260923","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1464-410X.2010.09555.x","article-title":"Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.","volume":"107","author":"Liotta","year":"2011","journal-title":"BJU Int"},{"key":"R43-20260923","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1007\/s13277-014-3012-8","article-title":"Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma.","volume":"36","author":"Asma","year":"2015","journal-title":"Tumour Biol"},{"key":"R44-20260923","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ni743","article-title":"Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo.","volume":"3","author":"Gavin","year":"2002","journal-title":"Nat Immunol"},{"key":"R45-20260923","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/cancers15082212","article-title":"Inflammatory networks in renal cell carcinoma.","volume":"15","author":"Kruk","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R46-20260923","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of type 1 conventional dendritic cells in cancer immunity.","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"key":"R47-20260923","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen presenting cells, critical for T cell immunity.","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"R48-20260923","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1385\/IR:22:2-3:299","article-title":"Adhesion molecule cascades direct lymphocyte recirculation and leukocyte migration during inflammation.","volume":"22","author":"Steeber","year":"2000","journal-title":"Immunol Res"},{"key":"R49-20260923","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer.","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R50-20260923","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s11255-013-0595-8","article-title":"Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells.","volume":"46","author":"Teng","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"R51-20260923","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","article-title":"The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.","volume":"168","author":"Belge","year":"2002","journal-title":"J Immunol"},{"key":"R52-20260923","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors.","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R53-20260923","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/320584a0","article-title":"Cachectin and tumour necrosis factor as two sides of the same biological coin.","volume":"320","author":"Beutler","year":"1986","journal-title":"Nature"},{"key":"R54-20260923","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","article-title":"Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology.","volume":"61","author":"Dumitru","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"R55-20260923","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.smim.2016.03.018","article-title":"Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells.","volume":"28","author":"Moses","year":"2016","journal-title":"Semin Immunol"},{"key":"R56-20260923","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ni.3141","article-title":"Responsiveness of B cells is regulated by the hinge region of IgD.","volume":"16","author":"\u00dcbelhart","year":"2015","journal-title":"Nat Immunol"},{"key":"R57-20260923","doi-asserted-by":"crossref","first-page":"e12830","DOI":"10.1111\/sji.12830","article-title":"Tumour-associated B cells in urothelial urinary bladder cancer.","volume":"91","author":"Zirakzadeh","year":"2020","journal-title":"Scand J Immunol"},{"key":"R58-20260923","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer.","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"R59-20260923","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R60-20260923","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"R61-20260923","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.4314\/ahs.v20i3.31","article-title":"Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia.","volume":"20","author":"Roya","year":"2020","journal-title":"Afr Health Sci"},{"key":"R62-20260923","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature08782","article-title":"B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.","volume":"464","author":"Ammirante","year":"2010","journal-title":"Nature"},{"key":"R63-20260923","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/pros.20549","article-title":"Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.","volume":"67","author":"Mihalyo","year":"2007","journal-title":"Prostate"},{"key":"R64-20260923","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.1000265","article-title":"Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model.","volume":"184","author":"Higham","year":"2010","journal-title":"J Immunol"},{"key":"R65-20260923","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","article-title":"Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen.","volume":"7","author":"Drake","year":"2005","journal-title":"Cancer Cell"},{"key":"R66-20260923","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4049\/jimmunol.1201271","article-title":"Differential requirement for CD70 and CD80\/CD86 in dendritic cell-mediated activation of tumor tolerized CD8 T cells.","volume":"189","author":"Bak","year":"2012","journal-title":"J Immunol"},{"key":"R67-20260923","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-0-387-72005-0_18","article-title":"Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA.","volume":"601","author":"Aalamian-Matheis","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"R68-20260923","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0022-5347(01)63093-3","article-title":"Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer.","volume":"160","author":"Troy","year":"1998","journal-title":"J Urol"},{"key":"R69-20260923","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CJI.0b013e31826b20b6","article-title":"Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte\/macrophage colony stimulating factor.","volume":"35","author":"Triozzi","year":"2012","journal-title":"J Immunother"},{"key":"R70-20260923","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"R71-20260923","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project.","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R72-20260923","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"The immunogenomic landscape of neuroendocrine prostate cancer.","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R73-20260923","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R77-20260923","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2019.09.029","article-title":"Prospective assessment of Vesical Imaging-Reporting and Data System (VI-RADS) and its clinical impact on the management of high-risk non\u2013muscle-invasive bladder cancer patients candidate for repeated transurethral resection.","volume":"77","author":"Del Giudice","year":"2020","journal-title":"Eur Urol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:51Z","timestamp":1790186571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":74,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044297","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}